BioLine Rx Ltd ADR BLRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day
-
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
-
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
-
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
-
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
-
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
Trading Information
- Previous Close Price
- $2.17
- Day Range
- $2.01–2.18
- 52-Week Range
- $2.01–4.09
- Bid/Ask
- $2.00 / $2.31
- Shares Outstanding
- 4.98M
- Market Cap
- $10.33M
- Volume/Avg
- 23,529 / 16,579
Key Statistics
- Price/Earnings (Normalized)
- 9.47
- Price/Sales
- 6.88
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 24
- Website
- https://www.biolinerx.com
Valuation
|
Metric
|
BLRX
|
|---|---|
Price/Earnings (Normalized) | 9.47 |
Price/Book Value | 0.94 |
Price/Sales | 6.88 |
Price/Cash Flow | — |
Price/Earnings
BLRX
Financial Strength
|
Metric
|
BLRX
|
|---|---|
Quick Ratio | 1.01 |
Current Ratio | 1.20 |
Interest Coverage | −9.68 |
Quick Ratio
BLRX
Profitability
|
Metric
|
BLRX
|
|---|---|
Return on Assets (Normalized) | −30.50% |
Return on Equity (Normalized) | −85.73% |
Return on Invested Capital (Normalized) | −38.39% |
Return on Assets
BLRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<v>z^@T | LOCK|W$kV | $123B | |||
| Moderna Inc
MRNA
| LOCK|jrX>P$X | LOCK|wl | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|y?#L^Z | LOCK|$?x!& | $78B | |||
| argenx SE ADR
ARGX
| LOCK|qk#&<?% | LOCK|%^^ | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|TXx>F? | LOCK|yV | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|jQC%#s | LOCK|#z@rc | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|g<TDYt<h | LOCK|mxy$ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|?H^$v# | LOCK|mB | $22B | |||
| Incyte Corp
INCY
| LOCK|>!QtG<c | LOCK|cx | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%?^>k$ | LOCK|?l | $14B |
United States